

**MEDICAL  
INTELLIGENCE  
UNIT**

# Fas Signaling

Harald Wajant, Prof., Ph.D.

Department of Molecular Internal Medicine  
Medical Clinic and Polyclinic II  
University of Wuerzburg  
Wuerzburg, Germany

LANDES BIOSCIENCE / EUREKAH.COM  
GEORGETOWN, TEXAS  
U.S.A.

SPRINGER SCIENCE+BUSINESS MEDIA  
NEW YORK, NEW YORK  
U.S.A.

# FAS SIGNALING

## Medical Intelligence Unit

Landes Bioscience  
Springer Science+Business Media, Inc.

ISBN: 0-387-32172-1

Printed on acid-free paper.

Copyright ©2006 Landes Bioscience and Springer Science+Business Media, Inc.

All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher, except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.

The use in the publication of trade names, trademarks, service marks and similar terms even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.

While the authors, editors and publisher believe that drug selection and dosage and the specifications and usage of equipment and devices, as set forth in this book, are in accord with current recommendations and practice at the time of publication, they make no warranty, expressed or implied, with respect to material described in this book. In view of the ongoing research, equipment development, changes in governmental regulations and the rapid accumulation of information relating to the biomedical sciences, the reader is urged to carefully review and evaluate the information provided herein.

Springer Science+Business Media, Inc., 233 Spring Street, New York, New York 10013, U.S.A.  
<http://www.springer.com>

Please address all inquiries to the Publishers:  
Landes Bioscience, 810 South Church Street, Georgetown, Texas 78626, U.S.A.  
Phone: 512/ 863 7762; FAX: 512/ 863 0081  
<http://www.eurekah.com>  
<http://www.landesbioscience.com>

Printed in the United States of America.

9 8 7 6 5 4 3 2 1

### Library of Congress Cataloging-in-Publication Data

Fas signaling / edited by Harald Wajant.

p. ; cm. -- (Medical intelligence unit)

Includes bibliographical references and index.

ISBN 0-387-32172-1

1. CD antigens. 2. Cellular signal transduction. I. Wajant, Harald. II. Title. III. Series: Medical intelligence unit (Unnumbered : 2003)

[DNLM: 1. Antigens, CD95. 2. Adaptor Proteins, Signal Transducing. 3. Membrane Glycoproteins. QW 573 F248 2006]

QR186.6.C42F37 2006

571.7'4--dc22

2006004030

# CONTENTS

Preface .....	ix
<b>1. FasL and Fas: Typical Members of the TNF Ligand and Receptor Family .....</b>	<b>1</b>
<i>Anja Krippner-Heidenreich and Peter Scheurich</i>	
The TNF Receptor and TNF Ligand Superfamilies .....	1
Identification of Fas and Its Ligand .....	2
The Membrane Receptor Fas .....	2
Fas Expression .....	5
The Fas Ligand .....	5
Membrane Bound and Soluble FasL .....	6
Receptor Ligand Complexes .....	7
Fas Signaling .....	8
<b>2. FasL-Independent Activation of Fas .....</b>	<b>13</b>
<i>Faustino Mollinedo and Consuelo Gajate</i>	
Fas Death Receptor Functions through Oligomerization and a Cascade of Protein-Protein Interactions .....	14
Fas Oligomerization without Interaction with Its Ligand FasL .....	15
Fas-Mediated Apoptosis Does Not Require the Participation of FasL .....	17
FasL-Independent Translocation and Capping of Fas into Membrane Rafts .....	18
FasL-Independent Activation of Fas by Unrelated Agents .....	19
How Are Fas Clusters Formed from Internal Signals? .....	21
<b>3. Role of Ceramide in CD95 Signaling .....</b>	<b>28</b>
<i>Volker Teichgräber, Gabriele Hessler and Erich Gulbins</i>	
Membrane Rafts .....	28
Ceramide-Enriched Membrane Platforms .....	29
Function of Ceramide-Enriched Membrane Platforms for CD95 Signaling .....	30
Mechanisms of Receptor Clustering .....	33
Ceramide-Enriched Membrane Platforms as General Signaling Motif .....	34
<b>4. Regulation of Fas Signaling by FLIP Proteins .....</b>	<b>38</b>
<i>Margot Thome</i>	
What Are the Structural Features of FLIP Family Proteins That Contribute to Their Anti-Apoptotic Function? .....	39
What Is the Molecular Function of Viral and Cellular FLIP? .....	39
What Is the Biological Function of the FLIP Proteins? .....	43
Is Altered FLIP Expression Linked to Pathologies? .....	45

<b>5. Fas-Induced Necrosis .....</b>	<b>51</b>
<i>Tom Vanden Berghe, Nele Festjens, Michael Kalai, Xavier Saelens and Peter Vandenabeele</i>	
Three Types of Programmed Cell Death .....	52
Fas Is an Important Regulator of Cell Death .....	52
Enzymatic Systems Involved in the Execution of Necrotic Events .....	60
<b>6. Fas—More Than an Apoptosis Inducer .....</b>	<b>69</b>
<i>Harald Wajant</i>	
Fas-Induced NFκB Activation .....	70
Fas and JNK Activation .....	81
FasL and Fas Stimulate Proliferation and Differentiation .....	83
Fas and FasL in Inflammation .....	85
Fas-Induced ERK Activation .....	86
<b>7. Retrograde Fas Ligand Signaling .....</b>	<b>97</b>
<i>Andreas Linkermann, Jing Qian and Ottmar Janssen</i>	
Fas Ligand as a Costimulatory Molecule .....	97
Fas Ligand as an Accessory Molecule in T Cell Development .....	98
The Molecular Basis for Retrograde Fas Ligand Signaling .....	99
Retrograde Signaling in Other TNF-Family Members .....	100
<b>8. FasL and Fas in Liver Homeostasis and Hepatic Injuries .....</b>	<b>103</b>
<i>Maria Eugenia Guicciardi and Gregory J. Gores</i>	
The Fas/FasL System in Liver Homeostasis and Regeneration .....	105
The Fas/FasL System in Liver Pathophysiology .....	106
Fas and the Development of Liver Fibrosis and Cirrhosis .....	112
<b>9. Fas-Activation, Development and Homeostasis of T Cells .....</b>	<b>118</b>
<i>Georg Häcker</i>	
Expression of Fas on T Cells and Susceptibility to Fas-Induced Apoptosis .....	118
Lpr and Gld Mice .....	118
Development and Selection of T Cells .....	120
Involvement of Fas-Signalling in the Activation of T Cells .....	120
Role of Fas for T Cell Homeostasis .....	121
Activation-Induced Cell Death .....	121
Role of Fas in the Accumulation of Unusual T Cells .....	123
Fas and 'Immune Privilege' .....	124
FasL as an Effector Molecule of Cytotoxic T Cells .....	124

<b>10. The FasL-Fas System in Disease and Therapy .....</b>	<b>128</b>
<i>Harald Wajant and Frank Henkler</i>	
Physiological Role of the FasL-Fas System .....	128
Pathophysiology of FasL and Fas .....	133
Therapeutic Potential of FasL and Fas Neutralizing Reagents and Fas Agonists .....	134
<b>11. Tools for Activation and Neutralization of Fas Signaling .....</b>	<b>145</b>
<i>Pascal Schneider</i>	
Fas Agonists .....	146
Inhibitors of the Fas-FasL System .....	150
<b>Index .....</b>	<b>157</b>

## EDITOR

**Harald Wajant**  
Department of Molecular Internal Medicine  
Medical Clinic and Polyclinic II  
University of Wuerzburg  
Wuerzburg, Germany  
Email: [harald.wajant@mail.uni-wuerzburg.de](mailto:harald.wajant@mail.uni-wuerzburg.de)  
*Chapters 6, 10*

## CONTRIBUTORS

Nele Festjens  
Molecular Signalling  
and Cell Death Unit  
Department of Molecular Biology  
Flanders Interuniversity Institute  
for Biotechnology  
University of Gent  
Gent, Belgium  
*Chapter 5*

Consuelo Gajate  
Centro de Investigacion del Cancer  
Instituto de Biologia Molecular  
y Celular del Cancer  
CSIC-Universidad de Salamanca,  
Campus Miguel de Unamuno  
Salamanca, Spain  
*Chapter 2*

Gregory J. Gores  
Division of Gastroenterology  
and Hepatology  
Mayo Medical School,  
Clinic and Foundation  
Rochester, Minnesota, U.S.A.  
Email: [gores.gregory@mayo.edu](mailto:gores.gregory@mayo.edu)  
*Chapter 8*

Maria Eugenia Guicciardi  
Division of Gastroenterology  
and Hepatology  
Mayo Medical School,  
Clinic and Foundation  
Rochester, Minnesota, U.S.A.  
*Chapter 8*

Erich Gulbins  
Department of Molecular Biology  
University of Essen  
Essen, Germany  
Email: [Erich.gulbins@uni-essen.de](mailto:Erich.gulbins@uni-essen.de)  
*Chapter 3*

Georg Häcker  
Institute for Medical Microbiology  
Technische Universität München  
München, Germany  
Email: [hacker@lrz.tu-muenchen.de](mailto:hacker@lrz.tu-muenchen.de)  
*Chapter 9*

Frank Henkler  
Department of Molecular Medicine  
Medical Clinic and Polyclinic II  
University of Wuerzburg  
Wuerzburg, Germany  
Email:  
[frank.henkler@mail.uni-wuerzburg.de](mailto:frank.henkler@mail.uni-wuerzburg.de)  
*Chapter 10*

Gabriele Hessler  
Department of Molecular Biology  
University of Essen  
Essen, Germany  
*Chapter 3*

Ottmar Janssen  
Institute of Immunology  
University of Kiel  
Kiel, Germany  
Email: [ojanssen@email.uni-kiel.de](mailto:ojanssen@email.uni-kiel.de)  
*Chapter 7*

Michael Kalai  
Molecular Signalling  
and Cell Death Unit  
Department of Molecular Biology  
Flanders Interuniversity Institute  
for Biotechnology  
University of Gent  
Gent, Belgium  
*Chapter 5*

Anja Krippner-Heidenreich  
Institute of Cell Biology  
and Immunology  
University of Stuttgart  
Stuttgart, Germany  
Email: anja.krippner@izi.uni-stuttgart.de  
*Chapter 1*

Andreas Linkermann  
Institute of Immunology  
University of Kiel  
Kiel, Germany  
*Chapter 7*

Faustino Mollinedo  
Centro de Investigacion del Cancer  
Instituto de Biologia Molecular  
y Celular del Cancer  
CSIC-Universidad de Salamanca  
Campus Miguel de Unamuno  
Salamanca, Spain  
Email: fmollin@usal.es  
*Chapter 2*

Jing Qian  
Institute of Immunology  
University of Kiel  
Kiel, Germany  
*Chapter 7*

Xavier Saelens  
Molecular Signalling  
and Cell Death Unit  
Department of Molecular Biology  
Flanders Interuniversity Institute  
for Biotechnology  
University of Gent  
Gent, Belgium  
*Chapter 5*

Peter Scheurich  
Institute of Cell Biology  
and Immunology  
University of Stuttgart  
Stuttgart, Germany  
Email:  
peter.scheurich@po.uni-stuttgart.de  
*Chapter 1*

Pascal Schneider  
Institute of Biochemistry  
University of Lausanne  
Epalinges, Switzerland  
Email: Pascal.Schneider@ib.unil.ch  
*Chapter 11*

Volker Teichgräber  
Department of Molecular Biology  
University of Duisberg-Essen  
Essen, Germany  
*Chapter 3*

Margot Thome  
Institute of Biochemistry  
University of Lausanne  
BIL Biomedical Research Center  
Epalinges, Switzerland  
Email: margot.thomemiazza@ib.unil.ch  
*Chapter 4*

Tom Vanden Berghe  
Department of Molecular Biology  
Flanders Interuniversity Institute  
for Biotechnology  
University of Gent  
Gent, Belgium  
*Chapter 5*

Peter Vandenabeele  
Department of Molecular Biology  
Flanders Interuniversity Institute  
for Biotechnology  
University of Gent  
Gent, Belgium  
Email:  
Peter.Vandenabeele@dmb.rug.ac.be  
*Chapter 5*

---

---

## PREFACE

---

---

More than 15 years ago the isolation of monoclonal antibodies inducing programmed cell death (apoptosis) in lymphoblastic cells and fibroblasts by the groups of Peter Krammer (Heidelberg) and Minako Yonehara (Tokyo) opened the door to a new field of apoptosis research. The identification of Fas/anti-APO-1 (CD95), a member of the TNF receptor superfamily, as the antigen recognized by the death-inducing antibodies and the growing overall interest in apoptosis encouraged a huge number of researchers to take a closer look at this molecule and its functions. This work did not only lead to a detailed understanding of Fas-induced apoptosis and Fas biology but has also defined principle mechanisms which are of broader relevance. For example, the research on Fas revealed a new category of protein-protein interaction domains (the death domain fold), established the “induced proximity” model of caspase activation and also uncovered basic mechanisms of activation of TNF receptors. Moreover, Fas malfunction or deregulated Fas signaling have been implicated in a growing list of pathologies making Fas and its ligand (FasL) attractive targets for the development of new therapies. Recent studies revealed that Fas is more than just a death inducer. It has been found that Fas mediates liver regeneration, proliferation, neuronal differentiation and inflammation. Thus, the Fas field shows more and more diversification over the initial apoptosis-related focus.

We hope that this book will help students and scientists gain a general overview and first-hand information on Fas signaling and Fas biology from leading scientists in the field. In the first part of this book the signaling mechanisms of Fas are summarized whereas the second part of the book focuses on specialized aspects of Fas biology and discusses the medical and biotechnological relevance of the molecule.

Finally, I want to thank the authors of each chapter for their pleasant cooperation and the staff of Landes Bioscience, in particular Cynthia Conomos and Kristen Shumaker, for their great help during the whole editorial process.

*Harald Wajant, Prof., Ph.D.*